GLPwatch
Identification of glycosylated exendin-4 analogue with prolonged blood glucose-lowering activity through glycosylation scanning substitution.
Bioorg Med Chem Lett · 2010
Last updated 2026-09-22Researchers modified a diabetes drug called exendin-4 by adding a sugar molecule (sialyl LacNAc) at position 28. The modified version showed longer-lasting effects in lowering blood sugar compared to the original drug.
AI summary of the abstract below.
| Journal | Bioorg Med Chem Lett, 2010 |
|---|---|
| Citations | 16 |
| Relative citation ratio | 0.46 |
| NIH percentile | 27 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
Exendin-4, a glucagon-like peptide 1 receptor agonist, is a potent therapeutic xenopeptide hormone for the treatment of type 2 diabetes. In order to further improve in vivo activity, we examined the introduction of sialyl N-acetyllactosamine (sialyl LacNAc) to exendin-4. The glycosylated analogue having sialyl LacNAc at position 28 was found to have improved in vivo activity with prolonged glucose-lowering activity.
Verbatim abstract via PubMed 20576431 ↗